Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif).

Trial Profile

Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif).

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Corticotropin (Primary) ; Interferon beta-1a; Interferon beta-1b; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2013 Primary endpoint 'Relapse-rate' has been met according to results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 10 Mar 2013 Results will be presented at the American Academy of Neurology's 65th Annual Meeting (AAN-2013) as announced in a media release issued by the American Academy of Neurology. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top